Project Grant R44CA306750
Award Date 8/1/25
Completion Date 7/31/28
Dollars Obligated $764K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75247, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,021,347 to Vigilant Laboratories LLC to develop a low-cost, point-of-care early detection test for oral cancer in low-resource settings. The key products to be delivered include: Prototypes of test strips for three biomarkers (CD44, total protein, and p16) to enable a commercializable point-of-care test. Vigilant Laboratories will work with a manufacturing partner,...
- The National Cancer Institute (NCI) awarded a $902,046 Project Grant under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program to Data Driven Bioscience Inc. on January 1, 2025. The grant supports the clinical validation of DuoSeq, a next-generation sequencing (NGS) platform that provides simultaneous DNA and RNA sequencing for the diagnosis of blood cancers. DuoSeq aims to overcome key limitations of existing NGS approaches by streamlining sample preparation,...
- This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
- This federal Project Grant award of $429,399 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund research to "RECALIBRATE THE LUNG CANCER POLICY MODEL (LCPM) TO ADDRESS LUNG CANCER RISK AND LUNG CANCER SCREENING PRACTICES IN REAL-WORLD POPULATIONS." The goal is to improve the LCPM's accuracy in estimating the health and economic impacts of low-dose computed tomography (LDCT) lung cancer screening by 1) adjusting the model to reflect...
- This $671,072 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel microdevice to measure malignant lipid signaling in single cells from clinical samples. The University of Washington will lead a multidisciplinary collaboration to create a "picoliter thin-layer chromatography" (PTLC) chip and supporting hardware, integrating bioengineering, chemistry, and oncology expertise. This...
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...